TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition
Advanced Science · 2026-01 · 13 (4)
DOI: 10.1002/advs.202505586 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 07.10.2025. Verfasst von Yanchen Zhang und 16 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Eye Health, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, 325027, China. Hauptthemen laut MEDLINE: Graves Ophthalmopathy, Aptamers, Nucleotide, Receptors, Thyrotropin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, the National Natural Science Foundation of China, Ministry and the province of Zhejiang Medical and Health Science and Technology Project.
Abstract (Originalsprache)
Graves' ophthalmopathy (GO) is an autoimmune disorder marked by orbital inflammation and tissue remodeling, leading to irreversible disfigurement and vision loss. The current first‐line glucocorticoid therapy remains palliative, underscoring the critical need for mechanism‐based interventions. Autoantibodies against thyrotropin receptor (TSHR) in GO patients highlight its therapeutic potential, yet TSHR inhibitor development faces challenges, including low potency, off‐target effects, and mechanistic constraints. To overcome this therapeutic void, YC3, a TSHR‐targeting nucleic acid aptamer, has been developed through an innovative approach that combines protein‐targeting cell‐SELEX with functional selection. YC3 exhibits nanomolar affinity alongside robust pharmacodynamic efficacy. In vitro, YC3 significantly reverses thyroid‐stimulating antibodies (TSAbs)‐driven hyperactivation in primary human orbital fibroblasts, thereby suppressing pathogenic hallmarks of fibroblasts. In vivo, therapeutic administration of YC3 significantly alleviates ocular symptoms in a GO mouse model. Mechanistic investigations reveal that YC3 binds to a previously unidentified allosteric site within the leucine‐rich repeat domain of TSHR, consequently inhibiting receptor activation. Collectively, this study not only identifies YC3 as a promising TSHR‐targeting therapeutic candidate but also unveils a novel allosteric site for next‐generation inhibitors. These findings highlight the potential of aptamers in both dissecting receptor mechanisms and uncovering cryptic druggable sites, thereby bridging structural biology with targeted drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Eye Health, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, 325027, China.
- Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Wenzhou, Zhejiang, 325000, China.
- Zhejiang Key Laboratory of Key Technologies for Visual Pathway Reconstruction, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, 325027, China.
- Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo and Biosensing, Hunan Research Center of the Basic Discipline for Cell Signaling, College of Biology, College of Chemistry and Chemical E…
ORCID-Profile: Wencan Wu
Förderung
- National Key R&D Program of China
- the National Natural Science Foundation of China
- Ministry and the province of Zhejiang Medical and Health Science and Technology Project
- Key science and technology program of Wenzhou
- National Key Research and Development Program of China
Zitieren
APA
Zhang, Y., Wu, E., Liu, W., Zeng, L., Ling, N., Wang, H., Li, Z., Yao, S., Pan, T., Li, X., Huang, Y., Li, X., Tu, Y., Yan, W., Wu, J., Ye, M., & Wu, W. (2026). TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition. Advanced Science, 13(4). https://doi.org/10.1002/advs.202505586
Vancouver
Zhang Y, Wu E, Liu W, Zeng L, Ling N, Wang H, et al. TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition. Advanced Science. 2026;13(4). doi:10.1002/advs.202505586
BibTeX
@article{Zhang2026,
author = {Zhang, Yanchen and Wu, Ende and Liu, Weibin and Zeng, Ling and Ling, Neng and Wang, Hongmei and Li, Zhixing and Yao, Shuang and Pan, Tonghe and Li, Xuanwen and Huang, Yate and Li, Xiaojing and Tu, Yunhai and Yan, Wentao and Wu, Jianzhang and Ye, Mao and Wu, Wencan},
title = {TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {4},
doi = {10.1002/advs.202505586}
}
EUVIMED